<DOC>
	<DOCNO>NCT01975480</DOCNO>
	<brief_summary>This open-label flexible-dose pilot study evaluate efficacy , safety , tolerability Pristiq ( desvenlafaxine ) outpatient subject diagnose Generalized Anxiety Disorder ( GAD ) without comorbidities secondary GAD . Primary trial objective evaluate efficacy Pristiq ( desvenlafaxine ) SNRI treatment 50 100 mg daily treatment GAD without comorbidities . Secondary trial objective determine whether treatment outcome GAD relate change cortical prefrontal activity norepinephrine .</brief_summary>
	<brief_title>Efficacy Serotonin-Norepinephrine Reuptake Inhibitor ( SNRI ) Treatment Prefrontality Patients With Generalized Anxiety Disorder ( GAD ) Other Comorbidities</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>The patient provide sign informed consent . Outpatients age 1865 ( extreme include ) . Patients primary diagnosis GAD accord DSM IV ( 300.23 ) criterion ( diagnosis make use Mini International Neuropsychiatric Interview ; MINI Version 6.0.0 ) . Patients comorbid anxiety disorder permit , long GAD judge primary diagnosis . Patients score HAMA ≥ 20 Screening Baseline , ≥ 10 psychic somatic anxiety factor . On basis physical examination , medical history , basic laboratory screening , patient , investigator 's opinion , suitable condition . Willing able attend study appointment correct time window . Any axis I diagnosis primary disorder previous six month . Alcohol drug abuse define DSM IV ( 300.23 ) within last six month . Mania , hypomania define DSM IV ( 300.23 ) . Any psychotic disorder . Eating disorder define DSM IV ( 300.23 ) . Any cognitive disorder dementia within 3 month baseline visit . Clinical interpretation apparent suicide risk . Continuation commencement formal psychotherapy . Current use commencement antidepressant anxiolytic medication . Failure 2 antidepressant ( either SSRIs SNRIs exclude treatment resistance . Patients , antidepressant anxiolytic prior study , discontinue two week prior entry study . Those fluoxetine , least 5 week . Patients herbal alternative treatment judge potentially anxiolytic psychobiological activity ( e.g . St. John 's Wort , Sadenosylmethionine ) , terminate usage agent two week prior enter study . Scores Hamilton Depression Rating Scale ( HAMD ) &gt; 15 , screen visit 1 Laboratory value screen medical history may consider clinical interpretation significant . Diseases could clinical interpretation interfere assessment safety , tolerability efficacy . Serious illness : Liver renal insufficiency , cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurological , infectious , neoplastic metabolic disturbance . If female , subject pregnant lactating intend become pregnant , within 30 day participate study ; intend donate ova time period . The subject receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . The patient , opinion investigator , unlikely comply clinical trial protocol unsuitable reason . Known allergy intolerance desvenlafaxine excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>